NRX Pharmaceuticals Inc (NRXP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $95.58M
Last updated: Nov 17, 2026 at 11:05 AM ET
NRX Pharmaceuticals Inc (NRXP) Stock Forecast
Analysts expect NRX Pharmaceuticals (NRXP) to earn -$0.80 per share in the fiscal year ending Dec 31, 2026, on revenue of $5.61M. Of 4 analysts, 4 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 4 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 1281.3%.
- Fiscal year ending Dec 31, 2026
- -$0.80
- EPS consensus, revenue $5.61M
- Fiscal year ending Dec 31, 2027
- -$0.35
- EPS consensus, revenue $77.49M
- Next report
- Nov 17, 2026
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.80 | -$0.80 to -$0.80 | 1 | $5.61M | $4.30M to $8.20M | 4 |
| Dec 31, 2027 | -$0.35 | -$0.35 to -$0.35 | 1 | $77.49M | $6.00M to $228.50M | 4 |
Quarterly Estimates
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.23 | -$0.49 to -$0.11 | 7 | $2.62M | $1.18M to $4.72M | 6 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 0 upward and 2 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$0.36.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.80 | -$0.80 | -$0.80 | -$0.36 | -$0.36 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.35 | -$0.35 | -$0.35 | $0.50 | $0.50 | N/A |
Frequently Asked Questions About NRXP
What is the NRXP stock forecast?
Consensus analyst estimates put NRX Pharmaceuticals's EPS at -$0.80 for the fiscal year ending Dec 31, 2026, on revenue of $5.61M. The consensus rating from 4 analysts is Buy.
How do analysts rate NRXP stock?
Of 4 analysts covering NRX Pharmaceuticals, 0 rate it Strong Buy, 4 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NRXP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.80, with estimates from -$0.80 to -$0.80 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.35, with estimates from -$0.35 to -$0.35 from 1 analyst.
What revenue do analysts expect from NRX Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $5.61M, with estimates from $4.30M to $8.20M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $77.49M, with estimates from $6.00M to $228.50M.
How many analysts cover NRXP?
4 analysts rate NRX Pharmaceuticals stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
NRXP pages: Overview, Earnings, Forecast, Financials, Competitors